Appointment will strengthen outsourcing of DUB-focused drug discovery services and capabilities to clients and partners
Dundee, UK, 07 November 2022: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced the appointment of Dr Hozefa Amijee as Head of Business Development (BD). As Ubiquigent enters the next phase of its development, the appointment will further improve access to the Company’s specialist CRO services and strengthen commercial partnerships, to meet the growing interest in the therapeutic potential of the DUB family of enzymes.
Hozefa joins Ubiquigent from Cellesce Ltd where, as Head of BD, he focused on growing partnerships and strategic alliances with top biotech and pharma companies, bringing the use of better patient-centric organoid models to drug discovery and development. He has over 20 years’ scientific and commercial experience in the life sciences industry, ranging from small biotech R&D to bespoke CRO and CDMO offerings, with Cambridge-based scientific roles at RxCelerate, Total Scientific and Senexis. Hozefa completed his PhD in Biochemistry at the University of Manchester, exploring amyloid aggregation inhibitors as a therapeutic strategy for Alzheimer’s disease treatment.
Dr Hozefa Amijee, Head of BD, Ubiquigent, said: “Ubiquigent is uniquely positioned to drive forward the discovery of novel DUB modulators, key to the development of powerful new medicines, and I am thrilled to be joining the Company at such a key stage in its commercial growth. I look forward to working closely with the team to support new and existing clients through the drug discovery process.”
Jason Mundin, Chief Executive Officer, Ubiquigent commented: “We are delighted to welcome Hozefa to the Ubiquigent team. Hozefa brings an impressive combination of technical know-how and commercial expertise, and we are confident that he will be invaluable in leading our continued development in the growing DUB field.”
To learn more about Ubiquigent’s DUB-focused drug discovery platform and services, contact services@ubiquigent.com.